PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35489270-13 2022 Enzymatic evaluation showed that both derivatives were potent dual MMP-2/VEGFR-2 inhibitors, particularly 8d (MMP-2; IC50 = 5.66 nM and VEGFR-2; IC50 = 6.65 nM), relative to the reference MMP-2 inhibitor NNGH (IC50 = 299.50 nM) and VEGFR-2 inhibitor sorafenib (IC50 = 4.92 nM). Sorafenib 250-259 matrix metallopeptidase 2 Homo sapiens 67-72 35489270-13 2022 Enzymatic evaluation showed that both derivatives were potent dual MMP-2/VEGFR-2 inhibitors, particularly 8d (MMP-2; IC50 = 5.66 nM and VEGFR-2; IC50 = 6.65 nM), relative to the reference MMP-2 inhibitor NNGH (IC50 = 299.50 nM) and VEGFR-2 inhibitor sorafenib (IC50 = 4.92 nM). Sorafenib 250-259 matrix metallopeptidase 2 Homo sapiens 110-115 31259702-7 2018 Sorafenib inhibited cell migration and invasion and decreased the expression of MMP-2 and MMP-9. Sorafenib 0-9 matrix metallopeptidase 2 Homo sapiens 80-85 32459093-5 2020 Herein, we developed an MMP2-activated and ATB0,+-targeted liposome with doxorubicin and sorafenib (DS@MA-LS) loaded for optimal tumor drug delivery for cancer therapy. Sorafenib 89-98 matrix metallopeptidase 2 Homo sapiens 24-28 30272354-6 2018 The combination of capsaicin and sorafenib also inhibited cell invasion and metastasis via upregulation of E-cadherin and downregulation of N-cadherin, vimentin, matrix metalloproteinase (MMP)2 and MMP9. Sorafenib 33-42 matrix metallopeptidase 2 Homo sapiens 162-193 29328399-9 2018 Western blot indicated that mitogen activated protein kinase signaling pathway proteins, vascular endothelial growth factor receptor, platelet derived growth factor receptor beta, Raf-1 proto-oncogene, serine/threonine kinase and matrix metallopeptidase 2 were regulated by miR-378a alone and to a greater extent when combined with sorafenib. Sorafenib 332-341 matrix metallopeptidase 2 Homo sapiens 230-255 30499465-12 2018 The phosphorylation of STAT3 and the expression of MMP-2 and MMP-9 were attenuated by ARHGAP24 ectopic expression and sorafenib treatment. Sorafenib 118-127 matrix metallopeptidase 2 Homo sapiens 51-56 28276313-0 2017 Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway. Sorafenib 64-73 matrix metallopeptidase 2 Homo sapiens 14-19 28276313-5 2017 Cells with a higher MMP-2 expression (SK-HEP-1 cells) were less sensitive to sorafenib than those with lower MMP-2 expression (HepG2 cells). Sorafenib 77-86 matrix metallopeptidase 2 Homo sapiens 20-25 28276313-6 2017 Cotreatment of cells with SB-3CT and sorafenib more strongly inhibited migration ability than with sorafenib treatment alone in both HCC cells with high and low expression of MMP-2. Sorafenib 37-46 matrix metallopeptidase 2 Homo sapiens 175-180 28276313-9 2017 With these results taken together, the current study demonstrates that inhibiting MMP-2 expression can enhance the antitumor effect of sorafenib in HCC cells with a high MMP-2 expression, which may provide a novel strategy to improve therapeutic efficiency in HCC. Sorafenib 135-144 matrix metallopeptidase 2 Homo sapiens 82-87 28276313-9 2017 With these results taken together, the current study demonstrates that inhibiting MMP-2 expression can enhance the antitumor effect of sorafenib in HCC cells with a high MMP-2 expression, which may provide a novel strategy to improve therapeutic efficiency in HCC. Sorafenib 135-144 matrix metallopeptidase 2 Homo sapiens 170-175 26244291-6 2015 Sorafenib significantly inhibited production of TGF-beta1, VEGF, IL-6, IL-8, MCP-1, and TNF-alpha and blocked the activation of migration-related signaling molecules, such as HIF-1alpha, p-STAT3, MMP2, and Ang-1. Sorafenib 0-9 matrix metallopeptidase 2 Homo sapiens 196-200 28746469-10 2017 Additionally, the phosphorylation levels of AKT, mTOR and MAPK as well as the expression levels of MMP-2 and MMP-9 were all decreased by a single treatment of IL-27 or sorafenib, and further decreased by the combined treatment of these two drugs. Sorafenib 168-177 matrix metallopeptidase 2 Homo sapiens 99-104 27998073-3 2016 In this study, we describe an easy method to construct a novel matrix metalloproteinase-2 (MMP-2) responsive nanocarrier, which can load hydrophobic agents (camptothecin and sorafenib) with high efficiency to exert synergistic efficacy for CRC treatment. Sorafenib 174-183 matrix metallopeptidase 2 Homo sapiens 63-89 27998073-3 2016 In this study, we describe an easy method to construct a novel matrix metalloproteinase-2 (MMP-2) responsive nanocarrier, which can load hydrophobic agents (camptothecin and sorafenib) with high efficiency to exert synergistic efficacy for CRC treatment. Sorafenib 174-183 matrix metallopeptidase 2 Homo sapiens 91-96 25862849-5 2015 Treatment with sorafenib significantly reduced HGF-enhanced expression of MMPs, suggesting that inhibition of MMP activity contributes to suppression of cellular motility and invasiveness of HepG2 cells. Sorafenib 15-24 matrix metallopeptidase 2 Homo sapiens 74-78 25557114-9 2015 Furthermore, sorafenib (2-6 mumol/L) dose-dependently decreased the expression of FoxM1, MMP-2, and Ki-67, and up-regulated that of p53 in the cells. Sorafenib 13-22 matrix metallopeptidase 2 Homo sapiens 89-94 25557114-13 2015 CONCLUSION: Sorafenib inhibits HCC proliferation and invasion by inhibiting MMP-2 and Ki-67 expression due to up-regulation of P53 and suppressing FoxM1. Sorafenib 12-21 matrix metallopeptidase 2 Homo sapiens 76-81 22918681-6 2013 Treatment with 7.5-muM sorafenib for 12 h markedly inhibited expression of TGFbeta1, TIMP-1, collagen I, and MMP2 mRNAs, but not of beta-PDGFR or type I TGFbetaR. Sorafenib 23-32 matrix metallopeptidase 2 Homo sapiens 109-113 23658488-4 2013 Anticancer activity of sorafenib against HuCC-T1 cells was evaluated by the proliferation test, matrix metalloproteinase (MMP) activity, cancer cell invasion, and angiogenesis assay in vitro and in vivo. Sorafenib 23-32 matrix metallopeptidase 2 Homo sapiens 122-125 23658488-7 2013 MMP-2 expression of HuCC-T1 cells gradually decreased according to sorafenib concentration. Sorafenib 67-76 matrix metallopeptidase 2 Homo sapiens 0-5